Seraph 100 is continuously being investigated in several EU and US clinical trials:
Safety and Performance Evaluation of Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) in the reduction of pathogen load from the blood in septic patients with suspected, life-threatening bloodstream infection. 24 clinical sites in 9 countries are participating in this study including major teaching hospitals and medical centers in Austria, Belgium, France, Germany, Italy, The Netherlands, Spain, Poland, and the United Kingdom.
Initiated at Uniformed Services University of the Health Sciences (USUHS), the program is an off-shoot of the Dialysis Like Therapy (DLT) program developed by DARPA which aimed at developing adjunctive therapies in a pandemic setting with no proven therapies. Seraph 100 is one of two blood purifying devices being tested in the PURIFY Program.
Safety and Performance Evaluation of Seraph 100 Microbind Affinity Blood Filter (Seraph 100) in the treatment of patients with COVID-19. 7 clinical sites in 3 countries are participating in this study to demonstrate the safety and performance of Seraph 100 in the clinical improvement of COVID-19 patient, measured by the reduction of established and suspected prognostic parameters